Vicore Pharma Holding AB (publ) (STO: VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
7.77
+0.21 (2.78%)
Nov 20, 2024, 5:29 PM CET
-42.53%
Market Cap 1.82B
Revenue (ttm) 104.24M
Net Income (ttm) -196.45M
Shares Out 234.58M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 854,412
Open 7.94
Previous Close 7.56
Day's Range 7.67 - 7.99
52-Week Range 6.92 - 24.10
Beta 0.68
Analysts n/a
Price Target n/a
Earnings Date Nov 5, 2024

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.